外泌体在胰腺癌中的研究进展

俊丽 王(内蒙古医科大学，中国；内蒙古医科大学附属医院，中国)
跃峰 李(内蒙古自治区人民医院，中国)
勤 董(内蒙古医科大学附属医院，中国)

摘要

胰腺癌作为消化系统中高病死率的恶性肿瘤，早期诊断率不高，患者确诊时常已发展至晚期，丧失很多根治性机会。据预测，胰腺癌将很快超过乳腺癌，成为欧盟癌症死亡的第三大原因。外泌体是直径为30~100nm的囊泡样小体，能通过与靶细胞的细胞膜融合、胞吞作用等方式将其携带的微小RNA（miRNA）、蛋白质等传递至靶细胞中，介导细胞间的信息交流并调控细胞的生理功能。近年来，发现外泌体在胰腺肿瘤的临床诊断与治疗中具有很重要的作用。论文针对外泌体在胰腺癌诊断与治疗中的作用进行探讨。

关键词

胰腺癌；外泌体；诊断；治疗

参考

Sergeant G, Vankelecom H, Gremeaux L, et al. Role of cancer stem cells in pancreatic ductal adenocarcinoma[J]. Nat Rev Clin Oncol, 2009,6(10):580-586.

Pan BT, Teng K, Wu C, et al. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes[J]. Cell Biol, 1985,101(3):942-948.

Johnstone R M, Adam M, Hammond J R, et al. Association of plasma membrane activities with released vesicles (exosomes)[J]. Biol Chem, 1987,262(19):9412-9420.

Whiteside T L. Tumor-derived exosomes and their role in cancer progression[J]. Adv Clin Chem, 2016, 74:103-141.

Tkach M, Théry C. Communication by Extracellular Vesicles: Where We Are and Where We Need to Go[J]. Cell, 2016(6):1226-1232.

Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer[J]. World J Gastroenterol, 2018(19):2047-2060.

Que R,Ding G, Chen J, et al. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma[J]. World J Surg Oncol, 2013(11):219.

Lai X, Wang M, Mcelyea S D, et al. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer[J]. Cancer Let, 2017(393):86-93.

Goto T, Fujiya M, et al. An elevated expression of serum exosomal microRNA-191, - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker[J]. BMC Cancer, 2018(1):116.

Melo Sa L L, Kahlert C, Fernandez AF.et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer[J]. Nature, 2015(7559):177-182.

Frampton AE, Prado MM, et al.Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden[J]. Oncotarget, 2018(27):19006-19013.

Li J, Chen Y, Guo X , et al. GPC1 exosome and its regulatory miRNAs are specific markers for the detection and target therapy of colorectal cancer[J]. Journal of Cellular&Molecular Medicine, 2017,21(5):838.

Jin H, Liu P, et al. Exosomal zinc transporter ZIP4 promotes cancer growth and is a novel diagnostic biomarker for pancreatic cancer[J]. Cancer Sci, 2018,109(9):2946-2956.

Tan A, De La Pena H, et al. The application of exosomes as a nanoscale cancer vaccine [J]. Int J Nanomedi, 2010(5): 889900.

Xiao L, Erb U, Zhao K, et al. Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer [J]. Oncoimmunology, 2017,6(6):e1319044.

Zech D, Rana S, Büchler MW, et al. Tumor-exosomes and leukocyte activation: an ambivalent crosstalk [J]. Cell Commun Signal, 2012,10(1):37.

Zhou M, Chen J, Zhou L, et al. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203 [J]. Cell Immunol, 2014,292(1-2):65-69.

Richards KE, Zeleniak AE, Fishel ML, et al. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells[J]. Oncogene,2017,36(13):1770-1778.

Aspe JR, Diaz Osterman CJ, Jutzy JMS, et al. Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant[J]. Extracell Vesicles, 2014(3):23244

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v4i6.7961